First multicenter real-world analysis of switching to next-generation enzyme replacement therapies in late-onset Pompe disease
This real-world study suggests that transitions between ERT preparations are generally feasible and associated with clinical stability in LOPD. Switching may represent a useful strategy in patients, particularly when efficacy concerns arise. Standardized prospective studies with systematic monitoring of immunogenicity and efficacy according to the 2024 EOPC guideline are recommended to confirm these findings.
Authors
- A Rosenbohm
- Stephan Wenninger (ORCID: https://orcid.org/0000-0001-8407-3642)
- Karl Christian Knop
- Natalia García-Angarita
- A. Güttsches
- N. Nguyen-Younossi
- Tanja Fangerau
- Daniel H. Mendelsohn
- Guljan Shahyrova
- Cornelia Kornblum
- Benedikt Schoser
Institutions
- Universität Ulm (DE)
- University Hospital Bonn (DE)
- Friedrich Baur Stiftung (DE)
- Hamburg Institut (Germany) (DE)
- BG University Hospital Bergmannsheil Bochum (DE)
- University and Rehabilitation Clinics Ulm (DE)
- University Hospital Ulm (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1007/s00415-026-13689-1
- Primary Topic
- Lysosomal Storage Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00